- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Osteoporosis
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 764KB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 155KB)
Romosozumab – March 2023
Romosozumab: Injection 105 mg in 1.17 mL single use pre-filled syringe; Evenity®
Last updated
30 June 2023